Abstract
Predicting COVID-19 severity is difficult, and the biological pathways involved are not fully understood. To approach this problem, we measured 4,701 circulating human protein abundances in two independent cohorts totaling 986 individuals. We then trained prediction models including protein abundances and clinical risk factors to predict adverse COVID-19 outcomes in 417 subjects and tested these models in a separate cohort of 569 individuals. For severe COVID-19, a baseline model including age and sex provided an area under the receiver operator curve (AUC) of 65% in the test cohort. Selecting 92 proteins from the 4,701 unique protein abundances improved the AUC to 88% in the training cohort, which remained relatively stable in the testing cohort at 86%, suggesting good generalizability. Proteins selected from different adverse COVID-19 outcomes were enriched for cytokine and cytokine receptors, but more than half of the enriched pathways were not immune-related. Taken together, these findings suggest that circulating proteins measured at early stages of disease progression are reasonably accurate predictors of adverse COVID-19 outcomes. Further research is needed to understand how to incorporate protein measurement into clinical care.
Competing Interest Statement
J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital and is the Founder of 5 Prime Sciences. The Lady Davis Institute has previously received funding from GlaxoSmithKline, Eli Lilly, and Biogen for research programs at Dr. Richards' laboratory unrelated to this manuscript. C.P. and M.H. are employees of SomaLogic.
Funding Statement
The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant number C18281/A29019], and the Fonds de Recherche Quebec Sante (FRQS). The Kaufmann lab's COVID-19 work is supported by the Canadian Institutes of Health Research /CITF (VR2-173203 and VS1-175561), the American Foundation for AIDS Research (AmFAR 110068-68-RGCV), the Canadian Foundation for Innovation, and FRQS. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility, and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. These funding agencies had no role in the design, implementation, or interpretation of this study. The measurement of proteomics using the SomaLogic panel was supported by the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) and by the Bill and Melinda Gates Foundation for the Mount Sinai cohort. J.B.R. and D.E.K. are supported by FRQS Merite Clinical Research Scholarships. C.-Y.S. is supported by a Lady Davis Institute / TD Bank Studentship Award. S.Z. is supported by a CIHR fellowship and an FRQS postdoctoral scholarship. G.B.L. is supported by a CIHR scholarship and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. T.N. is supported by Research Fellowships of the Japan Society for the Promotion of Science (JSPS) for Young Scientists. M.D. is supported by a clinician-researcher salary award from the FRQS. V.M. is supported by a Canada Excellence Research Chair.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All contributing cohorts to the present analyses received ethics approval from their respective research ethics review boards. The Biobanque Quebecoise de la COVID-19 (BQC19) received ethical approval from the IRB of the Jewish General Hospital (JGH) and the Centre Hospitalier de l'Universite de Montreal (CHUM). This research was reviewed and approved by the Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects (PPHS) under study number 20-00341. This research was considered minimal risk Human Subjects Research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code used in this analysis is available at https://github.com/chenyangsu/somalogic with additional information available upon request. The BQC19 is an Open Science Biobank. Instructions on how to access data for individuals from the BQC19 at the Jewish General Hospital site is available at https://www.mcgill.ca/genepi/mcg-covid-19-biobank. Instructions on how to access data from other sites of the BQC19 is available at https://www.bqc19.ca/en/access-data-samples.
